Global Market for Apoptosis Modulators in Oncology to Reach US$110.5 Billion by 2017, According to a New Report by Global Industry Analysts, Inc.

Share Article

GIA announces the release of a comprehensive global report on apoptosis markets. The global market for apoptosis modulators in oncology is forecast to reach US$110.5 billion by the year 2017. Growth in the market over the next few years will be primarily driven by huge unmet clinical needs in cancer treatment, and continuous R&D efforts that promise to help several apoptosis modulators to achieve desired clinical results and be set for commercial development. Focus on targeted cancer therapy and the need to overcome drug resistance will also drive future market prospects.

Apoptosis: A Global Strategic Business Report

Follow us on LinkedIn - A normal part of the development and health of multicellular organisms, apoptosis is a controlled natural process of cell death wherein cells self-destruct in response to natural stimuli designed to protect against virally infected cells, cells with damaged DNA and abnormal cell division. The importance of natural cell death can be put into perspective by the fact that apoptotic malfunction can result in triggering abnormal, uncontrolled and unregulated cell death called necrosis associated with degenerative diseases like Alzheimer's and Parkinson's disease. Also, defects in the apoptotic process results in inhibiting normal cell death, which in turn results in the development of autoimmune diseases such as, rheumatoid arthritis and lupus erythematosus. One of the leading causes of cancer is the defective apoptotic process wherein diseased cells that would normally die to prevent spread of infection, continues to mutate, transform and proliferate. Given the biological importance of cellular regulatory pathways, there exist massive levels of interest in research of apoptosis geared towards understanding and manipulating the apoptosis process to develop therapeutic interventions for major diseases such as cancer, AIDS, Stroke, heart disease, autoimmunity and degenerative diseases. apoptosis market is therefore witnessing spectacular growth with large pharmaceutical majors expatiating interest in apoptosis as drug targets. The possibility of developing drug compounds with the ability to control apoptosis holds unimaginable medical opportunities thus benefiting healthcare at large.

With over 365 apoptosis-modulating drug candidates in early to late stages of development, the future market potential for apoptosis modulating drugs is expected to be rosy. Continuous R&D efforts over the next few years has and will continue to help many of apoptosis modulators to achieve desired clinical results, thus helping the market attract tremendous commercial opportunities. The huge yet unmet medical needs in disease conditions, such as, cancer, cardiovascular diseases, organ transplant rejection, HIV/AIDS, degenerative & autoimmune diseases, will drive adoption and acceptance of new drugs among the medical community. Most of the clinical research until now has been directed towards developing several therapeutic ways to target apoptosis signaling pathways. This is primarily because what continue to be little understood are the morphological and molecular changes that occur during apoptosis. For instance, current knowledge about the mechanism of action of death signaling, the nature and/or identify of signals generated by dying cells to induce compensatory proliferation of neighboring cells are still little understood and therefore are topics of current research interest. Pathways to cell death therefore open up channels for manipulation of the apoptosis process thus providing medical science an opportunity to tackle diseases resulting from abnormalities in apoptosis process.

Cancer treatment currently represents the prime focus of most apoptosis research projects. The scenario can be thrown into sharp relief by the fact that of all pipeline agents for apoptosis, over 70% are anticancers. Exploiting apoptosis pathways for the treatment of cancer is attracting frenzied interest of late. Given the fact that bypassing natural apoptosis is a hallmark of the cancer disease and its growth, identification of the major regulators of apoptosis hold the key to defeating cancer. In other words, resistance of tumor cells to cell death as a result of defective apoptosis leading to excessive survival of mutated, damaged cells is the underlying cause for cancer. It is therefore of little surprise that current research focuses on unraveling the mystery behind the signaling pathways that help cancerous cells evade cell death to effectively develop new therapeutic targets. Additionally, activation of the natural apoptosis process as an anti-cancer approach is inviting increasing interest since such a strategy helps induce tumor regression unlike conventional pro-apoptotic agents which aid only preventing the spread of tumor cells, and which are incapable of discriminating against malignant and normal cells thus inducing higher risks of side effects.

Successful commercialization of apoptosis-based cancer therapeutics will open up the floodgates of dollar gains for apoptosis modulators in oncology market against a backdrop of rising incidences of cancer and unmet treatment needs. Anti-cancer drugs have already started to undergo clinical trials directed at molecular targets that have an important role to play in apoptosis process or/and apoptosis regulatory pathways. Rising popularity of targeted cancer therapy, which works by targeting cancer cells and leaving healthy cells undamaged, in response to the many disadvantages of chemotherapy bodes well for Apoptosis-Targeted Therapies for Cancer. Chemotherapy resistance that results from primary resistance and acquired resistance has also set the stage for interest in therapies that target unique molecular changes in cells.

As stated by the new market research report on Apoptosis, US represents the largest regional market for apoptosis modulators in oncology. The alarming number of new invasive cancer cases diagnosed in the US over the last few years makes the nation a market laden with immense potential for apoptosis modulators.

Major players in the marketplace include Abbott Laboratories, AbGenomics International, Inc., Aegera Therapeutics Inc., Amgen Inc., Anavex Life Sciences Corporation, ApopLogic Pharmaceuticals Inc, Ascenta Therapeutics, ArQule Inc., Bioniche Life Sciences Inc., Celgene Corporation, Chroma Therapeutics Ltd, Cancer Research Technology Ltd., EntreMed Inc., EpiCept Corporation, Exelixis Inc., Genextra S.p.A., Genta Inc., Infinity Pharmaceuticals Inc., ISIS Pharmaceutical Inc., Novartis Ltd., Pfizer Inc., Pharmacyclics, Inc., S*BIO Pte Ltd., Theraptosis SA, TopoTarget A/S, Xigen SA, and Æterna Zentaris GmbH.

The research report titled “Apoptosis: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, issues and growth drivers. The report provides market estimates and projections for apoptosis modulators in oncology in US$ Million across all major geographic markets including US, Canada, Europe (France, Germany, Italy, UK, Spain and Rest of Europe), Asia-Pacific, Latin America and Rest of World.

For more details about this comprehensive market research report, please visit –
http://www.strategyr.com/Apoptosis_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Public Relations
Visit website

Media